Methods of promoting fat loss comprising administering an ALK7 inhibitor
The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
1. A method for promoting fat loss in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutical preparation comprising a polypeptide that comprises a myostatin-binding domain of an ALK7 receptor, wherein the polypeptide selectively binds myostatin relative to BMP3 and competes with an ALK7 receptor to bind myostatin, wherein the preparation is substantially free of pyrogenic materials.
2. The method of claim 1 , wherein the mammal has obesity.
3. The method of claim 1 , wherein the mammal has type II diabetes.
4. The method of claim 1 , wherein the fat loss is not associated with a decrease in nutrient intake.
5. The method of claim 1 , wherein said myostatin-binding domain of an ALK7 receptor domain comprises an amino acid sequence that is at least 90% identical to a sequence of SEQ ID NO: 2.
6. The method of claim 1 , wherein said myostatin-binding domain of an ALK7 receptor domain comprises the amino acid sequence of SEQ ID NO: 2.
7. The method of claim 6 , wherein said myostatin-domain includes amino acid residues 26-100 of SEQ ID NO: 2, or a variant sequence thereof that retains myostatin-binding activity.
8. The method of claim 1 , wherein said polypeptide is a soluble ALK7 receptor.
9. The method of claim 8 , wherein said soluble ALK7 receptor includes an amino acid sequence shown in SEQ ID NO: 4 or 6.
10. The method of claim 1 , wherein said myostatin-binding domain binds myostatin with a K d of 1 μM or less.
11. The method of claim 1 , wherein said polypeptide is a fusion protein including, in addition to said myostatin binding domain, one or more polypeptide portions that enhance one or more of in vivo stability, in vivo half life, uptake/administration, tissue localization or distribution, formation of protein complexes, and/or purification.
12. The method of claim 11 , wherein said fusion protein includes an immunoglobulin Fc domain.
13. The method of claim 11 , wherein said fusion protein includes a purification method selected from: an epitope tag, a FLAG tag, a polyhistidine sequence, and a GST fusion.
14. The method of claim 1 , wherein said polypeptide includes one or more modified amino acid residues selected from: a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, an amino acid conjugated to a lipid moiety, and an amino acid conjugated to an organic derivatizing agent.